ZYBT

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-35.2K ExitQ1 2026 $35k -- $0.8501
Ken GriffinCitadel Advisors $4.5K AddQ4 2025 $4.5k -- $0.8501

News

globenewswire.comZhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiencyglobenewswire.comJun 4

prnewswire.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Resultsprnewswire.comApr 28

globenewswire.comZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structureglobenewswire.comApr 6

defenseworld.netShort Interest in Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Declines By 36.7%defenseworld.netMar 27

Trade ZYBT

About Zhengye Biotechnology Holding Limited

Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.

CEO: Songlin Song
IPO Date: Jan 7, 2025

Market Data

Open: $0.75
High: $0.7501
Low: $0.7302
Volume: 8.2K
Avg Volume: 274.3K
52W High: $13.08
52W Low: $0.68

Valuation

Market Cap: $35.5M
Enterprise Value: $265.4M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $703K
Revenue: $116.4M
Net Income: -$69.8M
Cash: $50.3M
Debt: $75.1M

Events

IPOJan 7

NASDAQ